Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net (loss) income | $(50,003) | $112,879 |
| Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: | ||
| Depreciation | 439 | 477 |
| Amortization and accretion of marketable securities | (365) | (494) |
| Stock-based compensation expense | 8,753 | 6,753 |
| Reduction in the carrying amount of right of use assets | 608 | 599 |
| Changes in assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s D&A?
- Stoke Therapeutics, Inc. (STOK) reported D&A of $439K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s D&A changed year-over-year?
- Stoke Therapeutics, Inc.'s D&A decreased by 8.0% year-over-year, from $477K to $439K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s D&A has grown at a 16.1% compound annual growth rate (CAGR), from $974K to $1.77M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Stoke Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude